Response to hydroxyurea therapy in beta-thalassemia

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Beta-thalassemia is a serious inherited blood disorder.
• Hydroxyurea (HU) therapy shows variable efficacy in beta-thalassemia patients.
• Predicting response to HU therapy is crucial for treatment optimization.

Purpose of the Study:

• To evaluate the clinical response to hydroxyurea (HU) therapy in beta-thalassemia patients.
• To investigate the molecular factors influencing HU therapy response.
• To identify predictors for successful HU treatment in beta-thalassemia.

Main Methods:

• Retrospective analysis of 18 beta-thalassemia patients treated with HU for a mean of 46 months.
• Evaluation of clinical response, including transfusion requirements and hemoglobin levels.
• Assessment of molecular background, including XmnI polymorphism, beta-globin mutations, and alpha-thalassemia deletions.

Main Results:

• 82% (9/11) of transfusion-dependent patients became transfusion-independent with HU therapy.
• 5 Thalassemia Intermedia patients on occasional transfusions became transfusion-independent.
• The XmnI polymorphism was associated with transfusion independence in most responders (7/9).

Conclusions:

• Hydroxyurea (HU) therapy is effective in achieving transfusion independence in a significant proportion of beta-thalassemia patients.
• The XmnI polymorphism is a key genetic factor associated with positive response to HU therapy.
• Further research is needed to fully elucidate the genetic factors influencing HU response in beta-thalassemia.